Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Caution in Interpreting Prognostic Genomic Factors in Underpowered Subgroups of Children with T-ALL.

Blood advances·2026
Same author

Persistent <i>BCR::ABL1</i>-positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome-positive ALL.

HemaSphere·2026
Same author

Descriptive Epidemiology and Prognosis of Pediatric Acute Leukemia in the Afro-Descendant Population of the French West Indies and French Guiana.

Cancer medicine·2026
Same author

Increased Susceptibility to Long-Term Complications in Leukemia Survivors Who Received Hematopoietic Stem Cell Transplantation During Adolescence.

Transplantation and cellular therapy·2026
Same author

Genomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia.

Leukemia·2026
Same author

First-year results of the International Leukemia/Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.

Haematologica·2026

Related Experiment Video

Updated: Jun 12, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Activating mutations in human acute megakaryoblastic leukemia.

Sébastien Malinge1, Christine Ragu, Veronique Della-Valle

  • 1Institut National de la Santé et de la Recherche Scientifique (INSERM), E0210, Paris, France.

Blood
|August 30, 2008
PubMed
Summary

Mutations in tyrosine kinase genes like JAK3 and MPL are common in acute megakaryoblastic leukemia (AMKL). These genetic alterations drive cancer development, offering potential therapeutic targets for leukemia treatment.

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jun 12, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Tyrosine kinase signaling pathways are frequently activated in human leukemias.
  • Acute megakaryoblastic leukemia (AMKL) is a challenging hematologic malignancy.
  • Understanding the genetic basis of AMKL is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate oncogenic mutations in key tyrosine kinase genes in AMKL.
  • To identify genetic differences between Down syndrome (DS)-associated and non-DS AMKL.
  • To functionally characterize novel mutations in AMKL.

Main Methods:

  • Sequence analysis of oncogenes (KIT, FLT3, JAK2, JAK3, MPL) in human AMKL samples.
  • Functional validation of mutations using BaF3 cell assays.
  • In vivo assessment of a novel MPL mutant via mouse bone marrow transplantation.

Main Results:

  • Mutations were identified in KIT, FLT3, JAK2, JAK3, and MPL genes in AMKL patients.
  • Mutations occurred more frequently in Down syndrome patients compared to non-DS patients.
  • JAK3 mutations were confirmed as activating, and a novel constitutively active MPL mutant (MPLT487A) was identified and induced myeloproliferative disease in mice.

Conclusions:

  • Genetic mutations in tyrosine kinases play a significant role in AMKL pathogenesis.
  • Down syndrome is associated with a higher frequency of these mutations.
  • Novel activating mutations in JAK3 and MPL provide insights into AMKL development and potential therapeutic strategies.